New study aims to crack the code on cancer drug resistance

NCT ID NCT07259226

Recruiting now Knowledge-focused Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well certain markers in tumors can predict whether a type of targeted cancer treatment called antibody-drug conjugates (ADCs) will work. About 400 adults with advanced breast, stomach, bladder, or lung cancer will provide tumor samples before and after treatment. The goal is to understand why some cancers become resistant to these drugs, which could help doctors choose better treatments in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma gastric cancer non-small cell lung carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER ADVANCED GASTRIC CANCER ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) ADVANCED UROTHELIAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Gustave Roussy Cancer Center
RECRUITING

Villejuif, 94805, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••